DELRAY BEACH, Fla.--(BUSINESS WIRE)--PositiveID Corporation (“PositiveID” or the “Company”) (NASDAQ: PSID) announced today that it has engaged Magellan Medical Technology Consultants (“Magellan”) to lead the U.S. Food and Drug Administration (“FDA”) submission process for the Company’s iGlucose 510(k). PositiveID and Magellan expect to submit the iGlucose 510(k), including required clinical research study and validation data, to the FDA in the third quarter of 2010.
